Thymosin β4 (full)
Full-length 43-aa Tβ4. Distinct from the TB-500 fragment; clinical trials in dry-eye and cardiac repair.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: TB4 · Timbetasin
Full-length 43-aa Tβ4. Distinct from the TB-500 fragment; clinical trials in dry-eye and cardiac repair.
Evidence Intelligence Score™
- Preclinical
- Pilot human← current
- RCT
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data6.3
- Safety maturityFollow-up depth and adverse-event signal5.3
- Mechanism confidencePathway specificity and clarity6.2
- Clinical readinessDistance to physician-prescribable use5.4
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts4.4
- Long-term dataFollow-up beyond initial trial windows3.6
- Translational confidenceAnimal → human signal preservation6.0
Early human signals exist, primarily from observational and pilot work — directional, not definitive.
Translational confidence is limited until pre-registered human trials reproduce the preclinical signal.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: directional. The next 12–24 months of registered trials will determine whether the early signal holds.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.